Comic Book Resources on MSN
This classic PS1 JRPG is 10/10, no notes
The PS1 era was a golden age for JRPGs. Not only were there heavy hitters like Final Fantasy VII, which sold over 15 million ...
Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one ...
The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares. Just after market close on Monday, Dyne announced that it has launched an underwritten public ...
Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...
Its No. 1 drug candidate did well in a clinical trial. It met both its primary and secondary endpoints. Before market open, Dyne announced that its zeleciment rostudirsen -- a treatment targeting the ...
Investors were haunted by the specter of share dilution. Just after market close on Monday, Dyne announced that it has launched an underwritten public offering of $300 million worth of its common ...
Briana White, the actress who portrays Aerith in Final Fantasy 7, has called on fans to stop tagging voice artists in spicy material featuring their characters. The discussion began after White saw ...
GameSpot may get a commission from retail offers. What's in a name? If you're Square Enix, a lot, as the studio has yet to reveal the full title of Final Fantasy 7 Remake. That reveal could be soon, ...
Eric Law is a Game Rant contributor from Pennsylvania, USA. An MMORPG-focused video game writer for Game Rant for two years and counting, Eric cut his teeth on gaming since he was a wee lad watching ...
Hosted on MSN
Dyne Therapeutics shares rise after announcing positive topline results for z-rostudirsen in phase 1/2 DMD trial
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now. On December 8, Dyne Therapeutics announced positive topline results from the Registrational Expansion ...
James Ratcliff joined Game Rant in 2022 as a Gaming News Writer. In 2023, James was offered a chance to become an occasional feature writer for different games and then a Senior Author in 2025. He is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results